Clinical factors associated with failed sentinel lymph node mapping in endometrial cancer
- PMID: 36249905
- PMCID: PMC9554829
- DOI: 10.1016/j.gore.2022.101080
Clinical factors associated with failed sentinel lymph node mapping in endometrial cancer
Abstract
Objective: Sentinel lymph node (SLN) mapping is a highly accurate surgical technique for detecting metastases in endometrial cancer. The objective of this study was to identify clinical factors associated with failed mapping.
Methods: All patients with endometrial cancer undergoing minimally-invasive staging and planned SLN biopsy from 1/1/2017 to 12/31/2020 at a single institution were identified retrospectively. Demographic, clinicopathologic and treatment data were obtained. Data were compared using descriptive statistics. Univariate and multivariable logistic regression were performed to identify predictors of failed mapping.
Results: 819 patients were identified with a mean age of 64.6 years (range 26-93) and mean BMI of 35.6 kg/m2 (range 18-68). Most (88.5 %, 725/819) had early-stage disease and endometrioid histology (82.3 %, 674/819). A majority (74.2 %, 608/819) had successful bilateral mapping, and 54 (6.6 %) had unsuccessful bilateral mapping. Increasing BMI was significantly associated with unsuccessful bilateral mapping: patients with BMI > 30 were more likely to have unsuccessful SLN mapping (p = 0.033). Among patients with known lymph node status (799/819), patients with macrometastases and micrometastases were more likely to have failed bilateral mapping compared to those with negative SLNs or isolated tumor cells (p = 0.013). On multivariable analysis, higher BMI and histology were associated with failed bilateral mapping (OR = 1.023, 95 % CI (1.005, 1.041) and OR = 1.678, 95 % CI (1.177, 2.394), respectively).
Conclusion: SLN mapping has a high success in patients undergoing minimally-invasive surgical staging for endometrial cancer. Increasing BMI, high risk histology, and lymph node metastases are risk factors for failed mapping.
© 2022 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- National Comprehensive Cancer Network. Uterine Neoplasms(Version 1.2022). . - PubMed
-
- Ballester M., Dubernard G., Lécuru F., Heitz D., Mathevet P., Marret H., Querleu D., Golfier F., Leblanc E., Rouzier R., Daraï E. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO) Lancet Oncol. 2011;12(5):469–476. - PubMed
-
- Eitan R., Sabah G., Krissi H., Raban O., Ben-Haroush A., Goldschmit C., Levavi H., Peled Y. Robotic blue-dye sentinel lymph node detection for endometrial cancer - Factors predicting successful mapping. Eur J Surg Oncol. 2015;41(12):1659–1663. - PubMed
-
- Cancer Facts & Figures 2021 | American Cancer Society [Internet]. [cited 2022 Apr 16];Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts....
-
- Glaser G., Dinoi G., Multinu F., Yost K., Al Hilli M., Larish A., Kumar A., McGree M., Weaver A.L., Cheville A., Dowdy S., Mariani A. Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer. Int J Gynecol Cancer. 2021;31(1):85–91. - PubMed
LinkOut - more resources
Full Text Sources